Loading stock data…
$23.52-0.72 (-2.97%)
Alamar Biosciences, Inc., a proteomics company, develops a proteomic liquid biopsy platform and sells instruments, consumables, and services to early detection of diseases.
| Metric (USD) | Q2 2026 | Q1 2026 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|
| Total Revenue | $29.43M↑ | $26.04M↑ | $16.16M↑ | $13.09M |
| Gross Profit | $17.72M↑ | $14.46M↑ | $8.58M↑ | $6.39M |
| Operating Income | -$13.53M↓ | -$12.35M↓ | -$7.92M↑ | -$8.55M |
| Net Income | -$13.20M↑ | -$21.32M↓ | -$7.02M↑ | -$7.66M |
Alamar Biosciences, Inc., a proteomics company, develops a proteomic liquid biopsy platform and sells instruments, consumables, and services to early detection of diseases. The company develops NULISA technology, a proteomics platform that detects an...